Bayer continues its cell and gene therapy push, enveloping different projects under one strategic roof while hunting new deals
Roughly five weeks after buying out Asklepios — also known as AskBio — for up to $4 billion, Bayer is hammering home its focus on cell and gene therapies.
The Big Pharma announced Wednesday that it is establishing a cell and gene therapy platform within its pharmaceuticals division in order to consolidate all of its related projects under one umbrella. Researchers will continue working and developing experimental drugs on their own, Bayer said, while the execs will lay out and define the overall strategy and look to swing some more deals.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,300+ biopharma pros reading Endpoints daily — and it's free.